Monopar Therapeutics (NASDAQ:MNPR) Earns Overweight Rating from Analysts at Piper Sandler

Equities researchers at Piper Sandler started coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note issued to investors on Friday,Benzinga reports. The brokerage set an “overweight” rating and a $72.00 price target on the stock. Piper Sandler’s price objective would indicate a potential upside of 194.36% from the stock’s previous close.

A number of other research analysts have also recently issued reports on MNPR. Rodman & Renshaw started coverage on shares of Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright raised their target price on Monopar Therapeutics from $6.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

Monopar Therapeutics Trading Down 2.8 %

NASDAQ MNPR opened at $24.46 on Friday. Monopar Therapeutics has a 12-month low of $1.54 and a 12-month high of $38.50. The firm’s fifty day simple moving average is $21.62 and its two-hundred day simple moving average is $10.55. The firm has a market capitalization of $129.10 million, a P/E ratio of -12.42 and a beta of 1.23.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. As a group, sell-side analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was purchased at an average cost of $16.25 per share, with a total value of $25,187.50. Following the acquisition, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 34.90% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.